A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2023-03-20
Target enrollment:
Participant gender:
Summary
This study is designed to assess safety, tolerability, and PK of single ascending doses (SAD)
of ABI-4334 in Part A and multiple-ascending doses (MAD) of ABI-4334 in Part B in healthy
subjects. Effect of food will also be evaluated in Part A.